Rite Aid Cites 'lack Of Credibility' To Reject Spear Point Capital's Acquisition Proposal

Rite Aid Corporation (RAD), a drug store chain, on Thursday confirmed that it previously rejected a non-binding, off-market proposal from Spear Point Capital Management to buy all of its shares.

Following an elaborated review, Board concluded saying "the proposal was not credible and did not warrant further exploration."

The store chain noted that Spear Point's proposal provided no evidence of financing, required multiple months of exclusivity and then called for Rite Aid to spend months soliciting competing offers.

In addition, the company said, Spear Point has no track record of acquiring public companies the size and complexity of Rite Aid.

Commenting on its future plans, Rite Aid said it will be responsive to all credible proposals that will enhance stockholder value.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Covid vaccine makers Pfizer Inc. and BioNTech SE announced a new $3.2 billion vaccine supply deal with the U.S. Government, as the country is bracing for a Covid outbreak this fall. Under the deal, the U.S. government will receive 105 million doses (30 µg, 10 µg and 3 µg) of Pfizer -BioNTech covid vaccines initially. The order may include adult Omicron-adapted COVID-19 vaccines. Samsung Electronics Co. has started the initial mass production of 3-nanometer or nm chips, which is considered as the most advanced chip in the world. In its move, the South Korean tech major beats rival Taiwan Semiconductor Manufacturing Co., the world's largest chip manufacturer, which is reportedly in the process to build one. Bryant Ranch Prepack Inc. is recalling certain Morphine Sulfate Extended-Release Tablets citing incorrect labeling, the U.S. Food and Drug Administration said. The recall involves one lot of Morphine Sulfate 30 mg Extended-Release tablets, and one lot of Morphine Sulfate 60 mg Extended-Release tablets to the consumer level.
Follow RTT